Login to Your Account



Aicuris partner Merck trials CMV fighter in global phase III

By Michael Fitzhugh
Staff Writer

Friday, July 25, 2014
Merck & Co. Inc. enrolled the first patient in a global phase III study of letermovir (MK-8228, AIC246), an experimental cytomegalovirus (CMV) antiviral it licensed from Aicuris GmbH.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription